Difference between revisions of "Team:ASIJ Tokyo"

Line 40: Line 40:
 
}
 
}
  
−
</style>
+
    </style>
−
<head>
+
    <head>
−
    <meta charset="utf-8">
+
          <meta charset="utf-8">
−
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
+
          <meta http-equiv="X-UA-Compatible" content="IE=edge">
−
    <link href="https://fonts.googleapis.com/css?family=Quicksand:300,400,500,700" rel="stylesheet">
+
          <link href="https://fonts.googleapis.com/css?family=Quicksand:300,400,500,700" rel="stylesheet">
−
</head>
+
    </head>
  
−
<body bgcolor: #bce2e8>
+
    <body bgcolor: #bce2e8>
 
         <div id="title">
 
         <div id="title">
 
             <p>A1-AT<br>de<span id="red">LIVER</span>y </p>
 
             <p>A1-AT<br>de<span id="red">LIVER</span>y </p>
Line 55: Line 55:
 
         <h1> Using Stem Cell and CRISPR Technology to Combat <br> Alpha-1 Antitrypsin Deficiency </h1>
 
         <h1> Using Stem Cell and CRISPR Technology to Combat <br> Alpha-1 Antitrypsin Deficiency </h1>
 
         </div>
 
         </div>
−
 
+
    </body>
−
        <div id="abstract">
+
−
          <h3> ABSTRACT </h3>
+
−
          <p> Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK. </p>
+
−
    </div>
+
−
 
+
−
</body>
+
 
</html>
 
</html>

Revision as of 07:03, 31 August 2018

A1-AT
deLIVERy

Using Stem Cell and CRISPR Technology to Combat
Alpha-1 Antitrypsin Deficiency